2022
Temporal distribution of Plasmodium falciparum recrudescence following artemisinin-based combination therapy: an individual participant data meta-analysis
Dahal P, Simpson J, Abdulla S, Achan J, Adam I, Agarwal A, Allan R, Anvikar A, Arinaitwe E, Ashley E, Awab G, Bassat Q, Björkman A, Borrmann S, Bousema T, Bukirwa H, Carrara V, Corsi M, Cot M, D’Alessandro U, Davis T, Deloron P, Desai M, Dimbu P, Djalle D, Djimde A, Dorsey G, Drakeley C, Duparc S, Edstein M, Espie E, Faiz A, Falade C, Fanello C, Faucher J, Faye B, de Jesus Fortes F, Gadalla N, Gaye O, Gil J, Gilayeneh J, Greenwood B, Grivoyannis A, Hien T, Hwang J, Janssens B, Juma E, Kamugisha E, Karema C, Karunajeewa H, Kiechel J, Kironde F, Kofoed P, Kremsner P, Lee S, Marsh K, Mårtensson A, Mayxay M, Menan H, Mens P, Mutabingwa T, Ndiaye J, Ngasala B, Noedl H, Nosten F, Offianan A, Ogutu B, Olliaro P, Ouedraogo J, Piola P, Plowe C, Plucinski M, Pratt O, Premji Z, Ramharter M, Rogier C, Rombo L, Rosenthal P, Sibley C, Sirima S, Smithuis F, Staedke S, Sutanto I, Talisuna A, Tarning J, Taylor W, Temu E, Thriemer K, Thuy-Nhien N, Udhayakumar V, Ursing J, van Herp M, van Lenthe M, van Vugt M, William Y, Winnips C, Zaloumis S, Zongo I, White N, Guerin P, Stepniewska K, Price R. Temporal distribution of Plasmodium falciparum recrudescence following artemisinin-based combination therapy: an individual participant data meta-analysis. Malaria Journal 2022, 21: 106. PMID: 35331243, PMCID: PMC8943927, DOI: 10.1186/s12936-021-03980-z.Peer-Reviewed Original ResearchConceptsDihydroartemisinin-piperaquineDays follow-upFollow-upEfficacy trialsRecrudescent infectionsRisk of recrudescenceAnti-malarial efficacy studiesUncomplicated Plasmodium falciparum malariaArtemisinin-based combination therapyDuration of follow-upPlasmodium falciparum malariaAnti-malarial treatmentMethodsIndividual patient dataFollow-up periodFollow-up time pointsCox regression modelsClinical efficacy trialsTreatment Efficacy TrialData meta-analysisTrial follow-upMalaria recrudescencePiperaquine dosingRecrudescent parasitaemiaFalciparum malariaOptimal follow-up period
2015
Ex vivo anti-malarial drug susceptibility of Plasmodium falciparum isolates from pregnant women in an area of highly seasonal transmission in Burkina Faso
Tahita M, Tinto H, Yarga S, Kazienga A, Traore/Coulibaly M, Valea I, Van Overmeir C, Rosanas-Urgell A, Ouedraogo J, Guiguemde R, van Geertruyden J, Erhart A, D’Alessandro U. Ex vivo anti-malarial drug susceptibility of Plasmodium falciparum isolates from pregnant women in an area of highly seasonal transmission in Burkina Faso. Malaria Journal 2015, 14: 251. PMID: 26088768, PMCID: PMC4474342, DOI: 10.1186/s12936-015-0769-1.Peer-Reviewed Original ResearchConceptsPregnant womenAnti-malarial drugsDrug sensitivity profilesParasite densityAnti-malarial drug susceptibilityDifferent drug sensitivity profilesUncomplicated Plasmodium falciparum malariaTreatment Efficacy TrialInfected pregnant womenArtemisinin-based combinationsPlasmodium falciparum malariaChloroquine-resistant isolatesHistidine-rich protein-2 assayPlasmodium falciparum isolatesGeometric mean IC50Low parasite densitiesP. falciparum parasitesTreatment of malariaFalciparum malariaRecurrent infectionsMean IC50Efficacy trialsFalciparum isolatesMethodsThe studyResistant parasites